SG11201906318WA - Algorithms and methods for assessing late clinical endpoints in prostate cancer - Google Patents
Algorithms and methods for assessing late clinical endpoints in prostate cancerInfo
- Publication number
- SG11201906318WA SG11201906318WA SG11201906318WA SG11201906318WA SG11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- prostate cancer
- drive
- pct
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 5
- 238000004422 calculation algorithm Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Image Processing (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458474P | 2017-02-13 | 2017-02-13 | |
| US201762473204P | 2017-03-17 | 2017-03-17 | |
| US201762578622P | 2017-10-30 | 2017-10-30 | |
| PCT/US2018/017790 WO2018148642A1 (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906318WA true SG11201906318WA (en) | 2019-08-27 |
Family
ID=61283339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912097QA SG10201912097QA (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
| SG11201906318WA SG11201906318WA (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912097QA SG10201912097QA (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200040400A1 (pt) |
| EP (1) | EP3580357B1 (pt) |
| JP (1) | JP7239477B2 (pt) |
| KR (1) | KR102376220B1 (pt) |
| CN (1) | CN110291206A (pt) |
| AU (1) | AU2018219354B2 (pt) |
| BR (1) | BR112019016652A2 (pt) |
| CA (1) | CA3049844C (pt) |
| CO (1) | CO2019008649A2 (pt) |
| ES (1) | ES2914727T3 (pt) |
| IL (1) | IL267911B2 (pt) |
| MX (1) | MX2019009027A (pt) |
| SG (2) | SG10201912097QA (pt) |
| WO (1) | WO2018148642A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019221930A1 (en) * | 2018-05-16 | 2019-11-21 | Opko Diagnostics, Llc | Methods for detecting prostate cancer pathology associated with adverse outcomes |
| CN109306867B (zh) * | 2018-11-19 | 2022-04-05 | 中国石油天然气股份有限公司 | 一种冲积扇沉积储层构型单元自动识别方法 |
| CN115427811A (zh) * | 2020-04-23 | 2022-12-02 | 日兴生物科技有限公司 | 前列腺癌诊断的相关方法 |
| KR102497196B1 (ko) | 2020-09-08 | 2023-02-07 | (주)유로테크 | 전립선암 진단 점수 계산 방법 및 그 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| US20080275652A1 (en) * | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| ES2373686T3 (es) | 2005-06-23 | 2012-02-07 | Biocartis Sa | Cartucho, sistema y procedimiento para diagnósticos médicos automatizados. |
| EP2407554A1 (en) * | 2010-07-14 | 2012-01-18 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Methods and kits for the diagnosis of prostate cancer |
| EP2809812A4 (en) | 2012-01-31 | 2016-01-27 | Genomic Health Inc | GENE EXPRESSION PROFILE ALGORITHM AND PROSTATE CANCER PROGNOSTIC DETERMINATION TEST |
| US9200328B1 (en) * | 2012-03-14 | 2015-12-01 | New York University | Methods and kits for diagnosing the prognosis of cancer patients |
| DK3303618T3 (da) * | 2015-05-29 | 2019-12-16 | Koninklijke Philips Nv | Fremgangsmåder til prognose af prostatacancer |
-
2018
- 2018-02-12 ES ES18707504T patent/ES2914727T3/es active Active
- 2018-02-12 KR KR1020197023192A patent/KR102376220B1/ko active IP Right Grant
- 2018-02-12 CA CA3049844A patent/CA3049844C/en active Active
- 2018-02-12 JP JP2019542696A patent/JP7239477B2/ja active Active
- 2018-02-12 CN CN201880011757.7A patent/CN110291206A/zh active Pending
- 2018-02-12 SG SG10201912097QA patent/SG10201912097QA/en unknown
- 2018-02-12 BR BR112019016652-1A patent/BR112019016652A2/pt unknown
- 2018-02-12 MX MX2019009027A patent/MX2019009027A/es unknown
- 2018-02-12 EP EP18707504.9A patent/EP3580357B1/en active Active
- 2018-02-12 WO PCT/US2018/017790 patent/WO2018148642A1/en active Application Filing
- 2018-02-12 SG SG11201906318WA patent/SG11201906318WA/en unknown
- 2018-02-12 AU AU2018219354A patent/AU2018219354B2/en active Active
- 2018-02-12 US US16/485,203 patent/US20200040400A1/en active Pending
-
2019
- 2019-07-08 IL IL267911A patent/IL267911B2/en unknown
- 2019-08-09 CO CO2019008649A patent/CO2019008649A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3049844A1 (en) | 2018-08-16 |
| SG10201912097QA (en) | 2020-02-27 |
| MX2019009027A (es) | 2020-01-27 |
| US20200040400A1 (en) | 2020-02-06 |
| JP2020507320A (ja) | 2020-03-12 |
| ES2914727T3 (es) | 2022-06-15 |
| CN110291206A (zh) | 2019-09-27 |
| EP3580357B1 (en) | 2022-04-27 |
| IL267911B2 (en) | 2023-08-01 |
| JP7239477B2 (ja) | 2023-03-14 |
| EP3580357A1 (en) | 2019-12-18 |
| WO2018148642A1 (en) | 2018-08-16 |
| BR112019016652A2 (pt) | 2020-03-31 |
| AU2018219354B2 (en) | 2024-06-27 |
| KR20190113814A (ko) | 2019-10-08 |
| CA3049844C (en) | 2022-06-28 |
| CO2019008649A2 (es) | 2019-10-31 |
| IL267911B1 (en) | 2023-04-01 |
| AU2018219354A1 (en) | 2019-07-25 |
| IL267911A (en) | 2019-09-26 |
| KR102376220B1 (ko) | 2022-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201908564RA (en) | Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201906318WA (en) | Algorithms and methods for assessing late clinical endpoints in prostate cancer | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201901841TA (en) | Targeting ligands | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201908396PA (en) | Methods of treating tumor | |
| SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201805157TA (en) | Targeted disruption of the mhc cell receptor | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
| SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201907607VA (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201408434QA (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer |